Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Whitehawk TherapeuticsWHWK -1.95%38 3-Year EBITDA Growth Rate is 50.10% as of Jun. 2026, which is 18% above its 10-year median of 42.40. GuruFocus rates WHWK with a GF Score™ of 38/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,129 Biotechnology companies, Whitehawk Therapeutics ranks better than 85.65% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 50.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Whitehawk Therapeutics was 50.10% per year. The lowest was -167.40% per year. And the median was 42.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Whitehawk Therapeutics 3-Year EBITDA Growth Rate Related Terms
WHWK vs MDWD, IMUX, IVVD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Whitehawk Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Whitehawk Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Whitehawk Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 50.10% mean?
Whitehawk Therapeutics (WHWK) has a 3-Year EBITDA Growth Rate of 50.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Whitehawk Therapeutics and its competitors. This is 18% above median its historical median of 42.40. According to the industry distribution chart, Whitehawk Therapeutics ranks #162 out of 1129 companies in the Biotechnology industry, placing it in the top 14.3%.
Is Whitehawk Therapeutics' 3-Year EBITDA Growth Rate too high?
Whitehawk Therapeutics' current 3-Year EBITDA Growth Rate of 50.10% is 18% above median its 10-year median of 42.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Whitehawk Therapeutics' value of 50.10% is 240.8% above this industry median. Based on the distribution chart, Whitehawk Therapeutics ranks #162 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Whitehawk Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' 3-Year EBITDA Growth Rate compare to MDWD and IMUX?
According to the Biotechnology industry distribution chart, Whitehawk Therapeutics ranks #162 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Whitehawk Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Whitehawk Therapeutics' value of 50.10% is 240.8% above this benchmark. While the company's 10-year median is 42.40 vs. the industry median of 14.70, Whitehawk Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Whitehawk Therapeutics's current 3-Year EBITDA Growth Rate of 50.10% is 240.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Whitehawk Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Whitehawk Therapeutics's current 3-Year EBITDA Growth Rate is 50.10%, which is 18% above median its own 10-year median of 42.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (WHWK) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $4.78 — trading 1670.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 50.10%, which is 18% above median its 10-year median of 42.40 and 240.8% above the Biotechnology industry median of 14.70. Whitehawk Therapeutics' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Whitehawk Therapeutics (WHWK), the current 3-Year EBITDA Growth Rate is 50.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?
Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued.
The current stock price of $4.78 is trading 1670.4% above its estimated GF Value™ of $0.27.
GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.
Key valuation signals for WHWK:
3-Year EBITDA Growth Rate: 50.10% (18% above median its 10-year median of 42.40)
GF Value™: $0.27 vs. price of $4.78 (1670.4% above fair value)
Industry Position: 240.8% above the Biotechnology median (#162 of 1129)
No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score
Get the complete analysis for WHWK
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WHWK has been successfully added to your 
